Mechanism of bronchoalveolar duct junction (BADJ) remodeling in idiopathic pulmonary fibrosis (IPF) as base for new pathogenetic therapy

E. Kogan, V. Tuong, S. Demoura (Moscow, Russian Federation)

Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Session: Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Session type: Thematic Poster Session
Number: 3489
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Kogan, V. Tuong, S. Demoura (Moscow, Russian Federation). Mechanism of bronchoalveolar duct junction (BADJ) remodeling in idiopathic pulmonary fibrosis (IPF) as base for new pathogenetic therapy. Eur Respir J 2008; 32: Suppl. 52, 3489

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013


Spontaneous pneumomedistinum & subcutaneous emphysema in idiopathic pulmonary fibrosis (IPF) with bronchial wall leak
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012


Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013

Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015



Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001

Idiopathic pulmonary fibrosis (IPF)
Source: ERS Course 2016
Year: 2016




Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016


The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015


Epithelium involvement and remodeling of interstitium in idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 745s
Year: 2006

The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004

Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006

Small airways impairment and air-trapping distinguish chronic hypersensitivity pneumonitis (CHP) from idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017

Arterial remodelling in patients with idiopathic pulmonary fibrosis (IPF) and the possible role of endothelial to mesenchymal transition (EndMT)
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021



Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005

Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009